CA1194802A - Pharmaceutical composition possessing antitumor activity - Google Patents
Pharmaceutical composition possessing antitumor activityInfo
- Publication number
- CA1194802A CA1194802A CA000413032A CA413032A CA1194802A CA 1194802 A CA1194802 A CA 1194802A CA 000413032 A CA000413032 A CA 000413032A CA 413032 A CA413032 A CA 413032A CA 1194802 A CA1194802 A CA 1194802A
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- tion
- tumor
- antitumor activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 9
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 6
- 239000010452 phosphate Substances 0.000 claims abstract description 6
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- KLZMUJRJFXYDCW-UHFFFAOYSA-N 2-[6-(diaminomethylideneamino)hexyl]guanidine;hydrochloride Chemical compound Cl.NC(N)=NCCCCCCN=C(N)N KLZMUJRJFXYDCW-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 suppositoria Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1982/000020 WO1984000105A1 (fr) | 1982-06-21 | 1982-06-21 | Preparation medicinale ayant un effet antitumoral |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1194802A true CA1194802A (en) | 1985-10-08 |
Family
ID=21616776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000413032A Expired CA1194802A (en) | 1982-06-21 | 1982-10-07 | Pharmaceutical composition possessing antitumor activity |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS59501110A (enExample) |
| CA (1) | CA1194802A (enExample) |
| CH (1) | CH660964A5 (enExample) |
| DE (1) | DE3249514T1 (enExample) |
| FR (1) | FR2535609A1 (enExample) |
| GB (1) | GB2134783B (enExample) |
| NL (1) | NL8220420A (enExample) |
| SE (1) | SE8400453L (enExample) |
| WO (1) | WO1984000105A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344846A (en) * | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| DE19628641C2 (de) * | 1996-07-16 | 1998-12-17 | Fresenius Ag | Verwendung von PHMB zur Behandlung von Tumorerkrankungen |
| RU2144024C1 (ru) * | 1998-10-28 | 2000-01-10 | Иркутский институт химии СО РАН | Способ получения фосфата полигексаметиленгуанидина |
| KR100557559B1 (ko) * | 1999-12-20 | 2006-03-03 | 에스케이 주식회사 | 폴리헥사메틸렌구아니딘 인산염 분말, 이의 제조방법 및이를 함유한 항균수지 |
| KR100725004B1 (ko) * | 1999-12-24 | 2007-06-04 | 에스케이 주식회사 | 살균소독제 조성물 및 이의 사용방법 |
| AT505312A1 (de) | 2007-05-15 | 2008-12-15 | Recticel Schlafkomfort Gmbh Sc | Polyurethan-werkstoff mit einer bioziden ausrüstung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3824288A (en) * | 1961-06-09 | 1974-07-16 | Hoffmann La Roche | Substituted hydrazine derivatives and process for the manufacture thereof |
| BR6457241D0 (pt) * | 1963-12-23 | 1973-06-26 | Rohm & Haas | Processo para a preparacao de t-octil-guanidinas |
| GB1492678A (en) * | 1975-08-11 | 1977-11-23 | Ici Ltd | Guanidine derivatives |
| JPS5341426A (en) * | 1976-09-27 | 1978-04-14 | Asahi Chem Ind Co Ltd | Fungicidal and bactericidal agents |
-
1982
- 1982-06-21 DE DE19823249514 patent/DE3249514T1/de not_active Withdrawn
- 1982-06-21 JP JP57503491A patent/JPS59501110A/ja active Pending
- 1982-06-21 CH CH90284A patent/CH660964A5/de not_active IP Right Cessation
- 1982-06-21 GB GB08403257A patent/GB2134783B/en not_active Expired
- 1982-06-21 NL NL8220420A patent/NL8220420A/nl not_active Application Discontinuation
- 1982-06-21 WO PCT/SU1982/000020 patent/WO1984000105A1/ru not_active Ceased
- 1982-10-07 CA CA000413032A patent/CA1194802A/en not_active Expired
- 1982-11-04 FR FR8218494A patent/FR2535609A1/fr active Granted
-
1984
- 1984-01-30 SE SE8400453A patent/SE8400453L/ not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE437931B (sv) | 1985-03-25 |
| GB2134783B (en) | 1985-10-30 |
| JPS59501110A (ja) | 1984-06-28 |
| GB2134783A (en) | 1984-08-22 |
| DE3249514T1 (de) | 1984-05-17 |
| WO1984000105A1 (fr) | 1984-01-19 |
| SE8400453L (sv) | 1985-03-25 |
| SE8400453D0 (sv) | 1984-01-30 |
| CH660964A5 (de) | 1987-06-30 |
| GB8403257D0 (en) | 1984-03-14 |
| FR2535609A1 (fr) | 1984-05-11 |
| NL8220420A (nl) | 1984-05-01 |
| FR2535609B1 (enExample) | 1985-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111909155B (zh) | 蛋白水解靶向嵌合体、提高其口服生物利用度的前药分子及应用 | |
| US7169412B2 (en) | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells | |
| US6312734B1 (en) | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells | |
| CA1194802A (en) | Pharmaceutical composition possessing antitumor activity | |
| EP0037486A2 (en) | Metal chelates of 1,4-bis(substituted-amino)-5,8-dihydroxy-anthraquinones | |
| US20080220093A1 (en) | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells | |
| AU2003251159B2 (en) | Ruthenium anticancer complexes | |
| US5219846A (en) | Treatment of human tumors utilizing compounds having a phosphoamides linkage or enol phosphate linkage | |
| Gold | Inhibition of Walker 256 intramuscular carcinoma in rats by administration of hydrazine sulfate | |
| US12214085B2 (en) | Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity | |
| CN114042043B (zh) | 一种雷公藤甲素线粒体靶向脂质体及其应用 | |
| CN110183504B (zh) | 一种具有肿瘤靶向性的吉西他滨前体药物及其制备方法和用途 | |
| CN115068501A (zh) | 一类抗肿瘤四价铂配合物前药及其制备方法和应用 | |
| CN114028579A (zh) | 核酸适配体-药物结合物PTK7-GEMs在制备治疗膀胱癌药物中的应用 | |
| CN108553455A (zh) | 三醛基间苯三酚缩氨基硫脲杂合体化合物在抗肿瘤药物中的应用 | |
| Swain et al. | Preparation of dendritic carboranyl glycoconjugates as potential anticancer therapeutics | |
| CN116621901A (zh) | 一种基于糖代谢标记的小分子探针及其在提高铂类药物靶向性方面的应用 | |
| CN105503984B (zh) | 一种Hedgehog信号通路抑制剂及其制备方法和应用 | |
| WO2023088062A1 (zh) | 厚朴酚和/或和厚朴酚芳环氨基取代类衍生物的抗低氧/缺氧损伤用途及药物组合物 | |
| CN104788391A (zh) | 肉桂酰中性红酰胺(ca-pz)及其制备与应用 | |
| 송수창 et al. | Synthesis and antitumor activity of poly (organophosphazene)/doxorubicin conjugates | |
| CN116621900B (zh) | 一种基于调控Mucin型O-糖基化靶向CRPC的四价铂氨基己糖配合物及其应用 | |
| CN103288673B (zh) | 一种铂配体及其配合物 | |
| CN113797353B (zh) | 一种放化疗联合治疗试剂及其制备方法 | |
| US20230391808A1 (en) | Phosphaphenalene-gold(i) complexes as chemotherapeutic agents against glioblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |